Science and Research

The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease

Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.

  • Yazgili, A. S.
  • Ebstein, F.
  • Meiners, S.

Keywords

  • Pa200
  • Psme4
  • proteasome
Publication details
DOI: 10.3390/biom12081150
Journal: Biomolecules
Number: 8
Work Type: Review
Location: ARCN, CPC-M
Disease Area: General Lung and Other
Partner / Member: FZB, HMGU
Access-Number: 36009043

DZL Engagements

chevron-down